How to appeal a Cigna lymphoma & leukemia (heme malignancies) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for lymphoma & leukemia (heme malignancies)

Cited policy: Cigna Adcetris (Brentuximab Vedotin) for HL and PTCL

Frontline HL stage III/IV with A+AVD (ECHELON-1). r/r cHL post auto-HSCT or after 2+ prior multi-agent regimens. Frontline ALCL (CD30+) sALCL with CHP. PTCL CD30+ ≥10%. Pediatric HL high-risk per AHOD1331. Hematologist Rx; ANC/peripheral neuropathy monitoring.

How Cigna denies lymphoma & leukemia (heme malignancies) — and how to counter it

Where Cigna pushes back: 1) Adcetris frontline experimental — use ABVD; 2) PTCL CD30 threshold not documented; 3) Pediatric off-label.

Counter-arguments that hold up: ECHELON-1 (Connors NEJM 2018;378:331; Ansell NEJM 2022 OS update) — A+AVD vs ABVD frontline stage III/IV cHL, OS benefit. FDA Mar 20, 2018 frontline approval. NCCN HL v2.2024 category 1. ECHELON-2 (Horwitz Lancet 2019;393:229) — A+CHP vs CHOP for CD30+ PTCL frontline — FDA Nov 2018. AHOD1331 supports pediatric HL use. CD30 IHC ≥10% threshold per FDA label and NCCN T-cell v2.2024.

What Cigna typically denies for lymphoma & leukemia (heme malignancies)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For lymphoma & leukemia (heme malignancies), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the lymphoma & leukemia (heme malignancies) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Imbruvica
• Calquence
• Brukinsa
• Jaypirca / pirtobrutinib
• Venclexta
• Rituxan / rituximab

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.